Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Liabeuf, Sophie ^a   Glorieux, Griet ^b   Lenglet, Aurelie ^a   Diouf, Momar ^a   Schepers, Eva ^b   Desjardins, Lucie ^a   Choukroun, Gabriel ^a,c   Vanholder, Raymond ^b   Massy, Ziad A ^a,d  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDOXYSULFATE; PARA CRESYLGLUCURORIDE; PARA CRESYLSULFATE; UNCLASSIFIED DRUG; UREMIC TOXIN;

AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; RISK ASSESSMENT; RISK FACTOR;

AGED; CRESOLS; DEMOGRAPHY; FEMALE; GLUCURONIDES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN BINDING; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; UREMIA;

EID: 84879472779     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067168     Document Type: Article

References (34)

1. Vanholder R, De Smet R, (1999) Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol. Aug 10(8): 1815-23.
2. Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S, (1994) Uremic toxicity: the middle molecule hypothesis revisited. Semin Nephrol. May 14(3): 205-18.
3. Vanholder R, Van Laecke S, Glorieux G, (2008) What is new in uremic toxicity? Pediatr Nephrol. Aug 23(8): 1211-21.
4. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, et al. (2008) A bench to bedside view of uremic toxins. J Am Soc Nephrol. May 19(5): 863-70.
5. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P, (2011) Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial. May-Jun 24(3): 327-37.
6. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, et al. (2007) P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. Feb 22(2): 592-6.
7. Curtius HC, Mettler M, Ettlinger L, (1976) Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr. Nov 3 126: 569-80.
8. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, et al. (2003) Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem. Mar 49(3): 470-8.
9. De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K, (2005) Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem. Aug 51(8): 1535-8.
10. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, et al. (2009) The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage. Am J Kidney Dis. Jul 16.
11. Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, et al. (2002) P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int. Dec 62(6): 1999-2009.
12. Meert N, Schepers E, Glorieux G, Van Landschoot M, Vanholder R, (2012) Novel method for simultaneous determination of p-cresylsulfate and p-cresylglucuronide: clinical data and pathophysiological implications Nephrol Dial Transplant. Jun 27(6): 2388-96.
13. Niwa T, Tsukushi S, Ise M, Miyazaki T, Tsubakihara Y, et al. (1997) Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 23(3-6): 179-84.
14. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, et al. (2010) Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. Apr 25(4): 1183-91.
15. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, et al. (2011) p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. Mar 26(3): 938-47.
16. Barreto FC, Barreto DV, Liabeuf S, Meert N, Temmar M, et al. (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. Oct 4(10): 1551-8.
17. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, et al. (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. Mar 51(3): 395-406.
18. K/DOQI (2002) Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. Feb 39(2Suppl 1): S1-266.
19. Zureik M, Temmar M, Adamopoulos C, Bureau JM, Courbon D, et al. (2002) Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens. Jan 20(1): 85-93.
20. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, et al. (1995) Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. Sep 26(3): 485-90.
21. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, et al. (1997) New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. Jul 25 132(2): 245-50.
22. Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, et al. (2010) Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens Jan 28(1): 163-9.
23. Harrell FE, Lee KL, Mark DB, (1996) Tutorial in biostatistics. Multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 15: 361-387.
24. Berge-Lefranc D, Chaspoul F, Calaf R, Charpiot P, Brunet P, et al. (2010) Binding of p-cresylsulfate and p-cresol to human serum albumin studied by microcalorimetry. J Phys Chem B. Feb 4 114(4): 1661-5.
25. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T, (2012) Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. Jun 403(7): 1841-50.
26. Massy ZA, Stenvinkel P, Drueke TB, (2009) The role of oxidative stress in chronic kidney disease. Semin Dial. Jul-Aug 22(4): 405-8.
27. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, et al. (2010) Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. Nov 25(11): 3693-700.
28. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, et al. (2010) p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. Jul 5(7): 1182-9.
29. Liabeuf S, Drueke T, Massy Z, (2011) Protein-Bound uremic toxins: new insight from clinical studies. Toxins. 3: 911-9.
30. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, et al. (2008) Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. May 73(10): 1174-80.
31. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, et al. (2009) Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 54: 459-67.
32. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, et al. (2006) Multicenter, randomized, double-blind, placebocontrolled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47: 565-77.
33. Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada, et al, (2004) Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 27: 121-6.
34. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, et al. (2006) Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 21: 2768-74.